Main Program

DAY 1:
Sunday, July 21, 2019
DAY 2:
Monday, July 22, 2019
DAY 3:
Tuesday, July 23, 2019

The 25th Annual Meeting of Japan Society of Gene and Cell Therapy

(E) Lectures in English  (J) Lectures in Japanese

DAY 1: Sunday, July 21, 2019

Symposium 1 (E)13:30-15:10 (Yasuda Auditorium)
“Gene Therapy for Neurological Diseases”
Chairs:
Shin-ichi Muramatsu (Jichi Medical School)
Hideki Mochizuki (Graduate School of Medicine, Osaka University)
1.
“βAPP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid
Rat Model of Alzheimer's Disease”
Satoru Tada (Graduate School of Medicine, Osaka University) 
2.
“Gene therapy for spinocerebellar ataxia”
Hitoshi Okazawa (Tokyo Medical and Dental University)
3.
“Recent Advancements in Gene Therapy With a Focus in Amyotrophic Lateral
Sclerosis and Rett Syndrome”
Petra Kaufmann (AVEXIS US/Novartis)
4.
“Gene Therapy Approaches for the Treatment of Angelman Syndrome”
Edwin Weeber (PTC Therapeutics)
Symposium 2 (E)15:10-16:50 Yasuda Auditorium
“Genetic Diseases”
Chairs:
Toya Ohashi (The Jikei University School of Medicine)
Torayuki Okuyama (National Center for Child Health and Development)
1.
“Current Status of Gene Therapy for Monogenic Disorders”
Torayuki Okuyama (National Center for Child Health and Development)
2.
“Anti-inflammatory therapy using multipotent mesenchymal stromal cells for
muscular dystrophy”
Yuko Nitahara-Kasahara (Nippon Medical School)
3.
“Gene therapy for inborn errors of metabolism”
Hiroshi Kobayashi (The Jikei University School of Medicine)
4.
“Progress of gene therapy for primary immunodeficiency”
Toru Uchiyama (National Center for Child Health and Development)
5.
“Gene therapy of genetic neurological disorders”
Hitoshi Osaka (Jichi Medical University)

DAY 2: Monday, July 22, 2019

Symposium 3 (J)9:00-10:40 (Yasuda Auditorium)
“Regulatory Science”
Chairs:
Masafumi Onodera (National Center for Child Health and Development)
Kenzaburo Tani (The Institute of Medical Science, The University of Tokyo)
1.
“Regulations of Gene and Cell Therapy in Japan”
Masafumi Onodera (National Center for Child Health and Development)
2.
“Current Status of Gene Therapy in Japan - Regulatory Issues”
Teruhide Yamaguchi (Nihon Pharmaceutical University/Kanazawa Institute
of Technology)
3.
"Points to consider in quality and preclinical aspects of gene therapy products"
Megumi Kawamoto (Pharmaceuticals and Medical Devices Agency)
4.
“The Minimum Consensus Package for Securing the Quality and Safety of
Human Cell-Based Therapeutic Products”
Yoji Sato (National Institute of Health Sciences)
Symposium 4 (E)9:00-10:40 (Koshiba Hall)
“JCA - JSGCT joint Symposium”
Chairs:
Yasufumi Kaneda (Graduate School of Medicine, Osaka University)
Masanori Hatakeyama (The Institute of Medical Science, The University of Tokyo)
1.
“Circumvention of targeted drug resistance in lung cancer”
Seiji Yano (Cancer Research Institute, Kanazawa University)
2.
“G-quadruplex as a molecular target for cancer therapy”
Hiroyuki Seimiya (The Cancer Chemotherapy Center, Japanese Foundation
for Cancer Research)
3.
“Development of diagnosis and treatment based on molecular pathogenesis of
gastrointestinal cancer”
Hiroshi Tazawa (Okayama University Hospital)
4.
“Elucidating a mechanism for RNA splicing driving human prostate cancer
progression”
Keisuke Nimura (Graduate School of Medicine, Osaka University)
Special Lecture (E)or (J)10:40-11:20 (Yasuda Auditorium)
Chairs:
Tomoki Todo (The Institute of Medical Science, The University of Tokyo)
“Cancer Genomic Medicine Brought by Molecularly Targeted Drugs”
 
    Hiroyuki Mano (National Cancer Center)
JSGCT Chairman’s Lecture (E)or (J)11:20-12:00 (Yasuda Auditorium)
Chairs:
Shigetaka Asano (Professor Emeritus: The University of Tokyo and Waseda
University)
 
    Tomoki Todo (The Institute of Medical Science, The University of Tokyo)
Special Symposium (E)13:30-15:00 (Yasuda Auditorium)
Chairs:
Hiroshi Fukuhara (Kyorin University Hospital)
Masatoshi Tagawa (Graduate School of Medicine, Chiba University)
1.
“Synergistic Cancer Therapies Utilizing Genetically-Engineered Oncolytic
Herpes Virus”
Robert Martuza (Massachusetts General Hospital and Harvard Medical School)
2.
“Drug-conjugated polymeric micelle in combination with oncolytic adenovirus
leads to synergistic antitumor effect”
Chae-Ok Yun (Hanyang University)
3.
“Intravenous Virotherapy: Inflaming Tumors via the Blood Stream”
Stephen Russell (Mayo Clinic College of Medicine)
Presidential Special Program (J) 15:10-17:10 (Yasuda Auditorium)
Chairs:
Yoshikatsu Eto (Advanced Clinical Research Center & Asian LSD Center,
Institute of Neurological Disorders)
Tastuya Kondo (Pharmaceuticals and Medical Devices Agency)
1.
“Clinical Translation of Cell Therapy for Congenital Heart Disease”
Hidemasa Oh (Okayama University Hospital)
2.
“Stem cell-based therapy for Parkinson's disease”
Jun Takahashi (Center for iPS Cell Research and Application, Kyoto University)
3.
“Intravenous injection of mesenchymal stem cells for spinal cord injury patients”
Osamu Honmou (Sapporo Medical University)
4.
“Autologous CD34-Positive Cell Therapy for Critical Limb Ischemia”
Atsuhiko Kawamoto (Translational Research Center for Medical Innovation)
5.
"Adoptive cell therapy with TCR-gene engineered T cells targeting NY-ESO-1"
Hiroshi Shiku (Mie University Graduate School of Medicine)

DAY 3: Tuesday, July 23, 2019

Symposium 5 (E)9:00-10:50 (Yasuda Auditorium)
“Cardiovascular Diseases & Regenerative Medicine”
Chairs:
Katsuto Tamai (Graduate School of Medicine, Osaka University)
Yoshikazu Yonemitsu (Kyushu University Graduate School of Pharmaceutical Sciences)
1.
“Physician-initiated clinical study of limb ulcers treated with a novel
functional peptide, SR-0379”
Hironori Nakagami (Graduate School of Medicine, Osaka University)
2.
“HMGB1 increases ectoderm-derived mesenchymal stem/progenitor cells in the
blood for necrotic tissue repair”
Katsuto Tamai (Graduate School of Medicine, Osaka University)
3.
“Derivation, Induction and Gene manipulation in Mesenchymal stem cell”
Takumi Era (Kumamoto University)
4.
“Scaffold-free Bio-3D Printing for Solid organ fabrication”
Koichi Nakayama (Saga University)
5.
“A RNA gene drug DVC1-0101 based on recombinant Sendai virus to treat
peripheral arterial disease”
Yoshikazu Yonemitsu (Kyushu University Graduate School of Pharmaceutical Sciences)
Symposium 6 (E)9:00-10:50 (Sanjo-Kaikan)
“Vector technology innovation towards clinical gene therapy”
Chairs:
Takashi Okada (The Institute of Medical Science, The University of Tokyo)
Hiroyuki Mizuguchi (Osaka University)
1.
“Chemistry, Manufacturing and Control of biopharmaceuticals”
Susumu Uchiyama (Graduate School of Engineering, Osaka University)
2.
“Allele expression vectors for assessment of disease-causing gene specific
RNAi”
Hirohiko Hohjoh (National Institute of Neuroscience, NCNP)
3.
“Functional analysis of adenovirus-associated RNAs and its application for an
oncolytic adenovirus”
Fuminori Sakurai (Graduate School of Pharmaceutical Sciences, Osaka University)
4.
“RNA virus-based episomal vector system and its applications in gene and cell
therapy”
Yumiko Komatsu (Institute for Frontier Life and Medical Sciences, Kyoto University)
Symposium 7 (E)12:30-14:20 (Yasuda Auditorium)
“Cancer”
Chairs:
Masatoshi Tagawa (Graduate School of Medicine, Chiba University)
Yasutomo Nasu (Okayama University)
1.
“Theranostics guided oncolytic virotherapy”
Kah Whye Peng (Mayo Clinic, USA)
2.
“Clinical development of oncolytic adenoviruses targeting advanced pancreatic
carcinoma”
Kazunori Aoki (National Cancer Center Research Institute)
3.
"Toca 511 and Toca-FC was associated with long term survival and a potential
immune cell signatures in a phase 1 study subset of recurrent High Grade
Glioma patients"
John Wood (Tokagen, USA )
4.
“Development of SOCS gene therapy for intractable cancers”
Satoshi Serada (Kochi University)
5.
“A phase I/II clinical trial of Ad-SGE-REIC for recurrent malignant glioma”
Kazuhiko Kurozumi (Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University)
Symposium 8 (E)12:30-14:20 (Sanjo-Kaikan)
“Genome Editing”
Chairs:
Yumi Kanegae (The Jikei University School of Medicine)
Mahito Nakanishi (National Institute of Advanced Industrial Science and Technology Science and Technology)
1.
“Structural basis for molecular mechanism of Cas9 and development of PAM-flex
Cas9 variants”
Osamu Nureki (Graduate School of Science, The University of Tokyo) 
2.
“Potential of base editing technology for gene therapy”
Keiji Nishida (Bioproduction Engineering Lab)
3.
“Precision gene editing in human pluripotent stem cells”
Knut Woltjen (Center for iPS Cell Research and Application, Kyoto University)
4.
“Application of Stealth RNA Vector to Genome Editing”
Mahito Nakanishi (National Institute of Advanced Industrial Science and Technology Science and Technology)
【 JSGCT2019 Meeting Secretariat 】
Division of Innovative Cancer Therapy, The Institute of Medical Science, The University of Tokyo
4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
Fax: +81-3-6409-2147
E-mail: jsgct2019@jsgt.jp
【 Congress Coordinator 】
Do Convention Inc.
5F, 2-23 Kandaawajicho, Chiyodaku, Tokyo 101-0063, JAPAN
Tel: +81-3-5289-7717 | Fax: +81-3-5289-8117
E-mail. jsgct2019-office@umin.ac.jp
Copyright © 2018 The 25th Annual Meeting of Japan Society of Gene and Cell Therapy. All Rights Reserved.